A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript

Blood

Volumn 101, Issue 6, 2003, Pages 2374-2376

  Santra, Madhumita ^a   Zhan, Fenghuang ^a   Tian, Erming ^a   Barlogie, Bart ^a   Shaughnessy Jr , John ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ARTICLE; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE EXPRESSION; GENE FUSION; GENE LOSS; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0037443417     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2801     Document Type: Article

References (9)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions, Nat Rev Cancer. 2002;2:175-187.
2. Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in myeloma. Blood. 2001;98:217-223.
3. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopaihy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
4. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in MM detectd by multiprobe interphase FISH. Blood. 2000;96:1505-1511.
5. Fonseca R, Oken M, Greipp P. The t(4;14)(p16; q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and MGUS. Blood. 2001;98:1271-1272.
6. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185-2191.
7. Moreau P, Facon T, Lelea X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-1583.
8. Keats J, Reiman T, Maxwell CA, et al. In multiple myeloma t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. Prepublished on October 3, 2002. DOI 10.1182/blood-2002-06-1675.
9. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417-1424.